摘要
HBV感染是全球重要的公共卫生问题。抗-HBc是人体感染HBV后产生的血清免疫学标志物之一。过去有研究表明,HBeAg阳性孕妇血清中低水平抗-HBc与婴儿免疫预防失败相关。此外,抗-HBc是与肝脏炎症活动及治疗效果相关的重要免疫学指标,可用于评估肝脏炎症、预测抗病毒疗效以及停药后持续应答。抗-HBc定量的临床应用,为乙型肝炎患者的个体化治疗开拓了新的方向。
Hepatitis B virus (HBV) infection is a global public health problem.Hepatitis B core antibody (anti-HBc) is one of the serum immunological markers in human body after HBV infection.Previous studies have shown that the low serum level of anti-HBc in HBeAg-positive mothers are associated with immunoprophylaxis failure in infants.In addition,anti-HBc is an important biomarker associated with liver inflammatory activity and therapeutic outcome and can be used to evaluate liver inflammation and predict the efficacy of antiviral therapy and sustained response after drug withdrawal.Anti-HBc quantification provides a new direction for individualized treatment of hepatitis B patients.
作者
尹雪如
佘格欣
侯金林
樊蓉
YIN Xueru;SHE Gexin;HOU Jinlin(Hepatology Unit and Department of Infectious Diseases,Nanfang Hospital,Southern Medical University,Guangzhou 510515,China)
出处
《临床肝胆病杂志》
CAS
北大核心
2019年第10期2156-2158,共3页
Journal of Clinical Hepatology
关键词
乙型肝炎病毒
乙型肝炎抗体
传染性疾病传播
垂直
hepatitis B virus
hepatitis B antibodies
infectious disease transmission,vertical